CDKN2A and lung adenocarcinoma: Notably, one patient with stage IV lung adenocarcinoma (patient number M24) had both MSI-H and TMB-H status, high PD-L1 expression (greater than 50%), and mutations in the CDKN2A and TP53 genes.